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Abstract 
Background: During the interpretation of genome sequencing data, some types of secondary findings are identi-
fied that are located in genes that do not appear to be related to the causes of the primary disease. Although these 
are not the primary targets for evaluation, they have a high risk for some diseases different from the primary disease. 
Therefore, they can be vital for preventing and intervention from such disease.
Results: Here, we analyzed secondary findings obtained from WES in 6 families with FCHL disease who had an 
autosomal-dominant pattern based on their pedigrees. These finding are found in CDKAL1, ITGA2, FAM111A, WNK4, 
PTGIS, SCN10, TBX20, DCHS1, ANK2 and ABCA1 genes.
Conclusions: Secondary findings are very important and must be considered different variants from sequencing 
results in a diagnostic setting. Although we have considered these variants as secondary findings, some of them may 
be related to the primary disease.
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Background
Secondary or incidental findings are described as patho-
genic (P) or more likely pathogenic variants with a phe-
notype unrelated to the primary disease [1]. These data 
are mainly obtained in families that undergo whole-
genome or whole-exome sequencing (WGS/WES) due 
to an affected family member. These findings can be 
used for the early diagnosis of a new disease in the fam-
ily before its symptoms appear, thus preventing mortality 
from latent diseases and leading to increased life expec-
tancy [2].
Familial combined hyperlipidemia (FCHL) is a com-
mon familial lipoprotein disorder associated with prema-
ture cardiovascular disease (CVD) [3]. The frequency of 
FCHL in the general population is 1–3%, and in patients 
with a previous history of myocardial infarction (MI), it 
is 20–38% [4]. This disease is a heterogeneous disorder 
caused by a defect in the metabolism of chylomicrons, a 
defect in lipolysis or a decrease in fatty acid incorpora-
tion by adipose tissue, overproduction of very low-den-
sity lipoprotein (VLDL) and Apo B100’s overexpression 
in individuals with normal BMI [5]. FCHL can be accom-
panied by other metabolic disorders such as obesity, 
hypertension, non-alcoholic fatty liver disease (NAFLD), 
metabolic syndrome (MS), insulin resistance (IR) and 
type 2 diabetes mellitus (T2D) [6].
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Although FCHL is a complex disease, there are families 
with several affected members who may follow a mono-
genic pattern of inheritance. Several genes might con-
tribute to the FCHL phenotype, including the upstream 
transcription factor 1 gene (USF1)1, paraoxonases 
(PON1), protocadherin-related 15(PCDH150), Fork-
head box C2(FOXC2), low-density lipoprotein receptor 
(LDLR), glycosylphosphatidylinositol-anchored HDL 
binding protein 1(GPHDLBP1) and angiopoietin-like 
3 (ANGPTL3) [7, 8]. FCHL diagnosis is therefore chal-
lenging because of a multifactorial pattern of inheritance 
with genetic and environmental factors involvement, but 
in some families there is a monogenic pattern of inherit-
ance, and in these families with a specified pedigree and 
several members of affected individual, WES can be used 
for FCHL diagnosis to detect the major pathogenic vari-
ants associated with the disease [11]. However, in addi-
tion to the major pathogenic variants, there may be other 
important variants unrelated to early disease and indicate 
a risk of other diseases in the family. Therefore, after ana-
lyzing the WES results for main variants in related genes 
[12, 13], we decided to evaluate the secondary findings 
obtained in 6 different families with an autosomal-domi-
nant inheritance of FCHL based on their pedigrees.
Methods
Study population
This study was performed on six families with a reoccur-
ring and unusual constellation of juvenile-onset FCHL 
and early-onset coronary heart disease. All of the six 
families in this study had an autosomal-dominant pat-
tern of inheritance based on their pedigrees. FCHL diag-
nosis was confirmed in accordance with the 2016 ESC/
EAS (European Society of Cardiology/ European Athero-
sclerosis Society) Guidelines for dyslipidemias. The study 
was approved by the local university ethics committee. 
Besides, all participants in the study signed a consent 
form. Based on Fig. 1, we selected one member from each 
family for evaluation by WES) they are marked with an 
arrow in the pedigrees shown in Fig. 1. After evaluating 
family members and collecting clinical and laboratory 
data, genomic DNA was extracted from 5  ml of blood 
containing EDTA anticoagulant.
Whole‑exome sequencing
Six patients were screened using sequencing all exons 
of protein encoding regions and some other critical 
genomic regions. WES has been read 100 million times 
using the Illumina Sequencer. In total > 95% of the target 
Fig. 1 pedigrees of studied pedigrees from 1 to 6, Circles indicate female family members and squares male family members; slashes indicate that 
the family member is deceased. Family members with FCHL disease are indicated by solid symbols and those without FCHL indicated by open 
symbols. FCHL, familial combined hyperlipidemia
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areas with acceptable sensitivity of about 99% has been 
investigated. WES can be used for some variants detec-
tion in genome and these variants are including gain/
loss mutations, start loss or frame shift variants, in-frame 
insertions or deletions, variants within the intron–exon 
boundary, missense variants in exons and some lateral 
sequences in target areas. Following this, bioinformat-
ics analysis was performed using international databases 
and some bioinformatics software. At this stage, various 
filters are used for the raw output to reduce the data to 
a limited number. Subsequent identifying related muta-
tions, secondary findings were studied, and their char-
acteristics were determined by some international 
databases such as OMIM, Gene Cards and MalaCards. In 
the next step we used some prediction software’s such as 
SIFT, Mutation Taster, FATHMM and DANN for inves-
tigation and prediction of identified variants on the cell’s 
biological function.
Results
All affected family members in this study had coro-
nary artery diseases (CHD) events before the age of 
50  years. Also they had total cholesterol > 240  mg/dl, 
LDL > 160  mg/dl and TG > 133  mg/dl, and according to 
the 2016 ESC/EAS guidelines associated with manage-
ment of dyslipidemias, they had the standard criteria 
for FCHL. The diagnosis of genetic diseases using the 
WES technique provides numerous data and some of 
these findings are important for follow-up. Our study 
showed some likely pathogenic/pathogenic unrelated 
variants to FCHL. At least one secondary finding was 
identified in each family, with a disease-causing effect in 
some prediction software which are shown in Table  1. 
These findings include CDKAL1 (NM_017774: exon3: c. 
G116A: p. R39Q, ITGA2(NM_002203: exon4: c. A352G: 
p. I118V), FAM111A (NM_001312911: exon4:c.C1216T: 
p Q406X), WNK4(NM_032387: exon1: c.178delA: p. 
S60fs), PTGIS (NM_000961: exon1: c. G62A: p. R21H), 
SCN10(NM_001293307: exon26: c.5116_5117del: p. 
L1706fs), TBX20(NM_001077653: exon4: c. G577A: 
p. G193S), DCHS1(NM_003737: exon10: c. G4330A: 
p. A1444T), ANK2(NM_001148: exon38:c.C6749T: 
p. S2250L), ABCA1(NM_005502: exon5: c.C357A: p. 
D119E). The interpretation of these variants is given in 
Table 1.
Discussion
The American College of Medical Genetics and Genom-
ics (ACMG) has published instructions on report-
ing secondary findings in clinical exome and genome 
sequencing [14]. Accordingly, only pathogenic or, most 
likely, pathogenic variants are reported as secondary 
findings. It is estimated that 1–4% of all individuals who 
have had an exome or genome sequencing have a second-
ary finding [15, 16]. Therefore, it can be said it is a form 
of screening that should be analyzed using a diagnostic 
Table 1 Secondary findings in prediction software’s in clinical genomic whole-exome sequencing from families with FCHL
B: Benign, T: tolerate, D: disease causing, N: natural, S: stop gain, F: frame shift





1 Diabetes mellitus non-insulin dependent D T D D CDK5 Regulatory Subunit Associated Protein 1-Like 1( 
CDKAL1) (NM_017774: exon3: c.G116A: p.R39Q)
2 Platelet-type bleeding disorder D D D N Integrin Subunit Alpha 2(ITGA2)(NM_002203:exon4:c.
A352G:p.I118V)
Gracile bone dysplasia Kenny–Caffey syndrome 
type 2
D T N D FAM111 Trypsin-Like Peptidase A (FAM111A) 
(NM_001312911:exon4:c.C1216T:p Q406X)
3 Pseudohypoaldosteronism, type IIB F F F F WNK Lysine Deficient Protein Kinase 4(WNK4) 
(NM_032387: exon1: c.178delA: p.S60fs)
4 Hypertension D T N N Prostaglandin I2 Synthase (PTGIS)(NM_000961: exon1: 
c. G62A: p. R21H)
Episodic pain syndrome, familial, F F F F Sodium Voltage-Gated Channel Alpha 
Subunit 10(SCN10) (NM_001293307: 
exon26:c.5116_5117del:p.L1706fs)
Atrial septal defect 4 (ASD4) D D D D T-Box Transcription Factor 20(TBX20) (NM_001077653: 
exon4:c.G577A:p.G193S)
Mitral valve prolapse 2 MVP2 D T D D Dachsous Cadherin-Related 1(DCHS1)(NM_003737: 
exon10:c.G4330A:p.A1444T)
5 Cardiac arrhythmia, ankyrin-B-related,;Long QT 
syndrome
D D D D Ankyrin 2(ANK2) (NM_001148: exon38:c.C6749T: 
p.S2250L)
6 Coronary artery disease & HDL deficiency D T D D ATP Binding Cassette Subfamily A Member 1(ABCA1) 
(NM_005502: exon5: c.C357A: p.D119E)
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approach [17]. It may provide patients with an additional 
clinical follow-up for a special health condition [18]. 
However, the interpretation of these findings has always 
been challenging. Researchers and physicians have never 
reached a similar conclusion about them. On the one 
hand, identifying secondary findings can be a clue for 
patients and physicians to prevent diseases that may be in 
the relatively early stages. Also, genetic variants diagnosis 
associated with certain diseases before the phenotype is 
revealed can have a psychological burden on individuals 
[20, 21].
To date, various studies have been performed on a 
considerable number of samples among different popu-
lations, and the data obtained confirm the presence of 
a change in the number of secondary findings between 
different groups. For example, Jalkh et  al. have identi-
fied 4262 variants in the 59 selected genes among 280 
Lebanese individuals, of which 6% were pathogenic or 
possibly pathogenic [22]. Xue et al. have reported a fre-
quency of 11% of secondary findings among 179 subjects 
[23], and in the examination of 1,000 WES belonging 
to Europeans/African people, they have obtained 1.2 to 
3.4% of secondary findings [24]. This difference indicates 
that secondary findings’ evaluation depends on vari-
ous factors such as study design, sequencing technology, 
experimental group and mainly data interpretation. In 
this study, secondary findings related to cardiac diseases 
were identified in some samples, and these findings may 
be important, being related to the underlying disease. 
One of the secondary findings was a mutation associ-
ated with mitral valve prolapse in the DCHS1 (dachsous 
cadherin-related 1) gene. Patients with MVP2 have non-
syndromic MVP with an autosomal-dominant pattern 
and severe variable expression [25]. Neubauer et al. have 
studied five young sudden unexplained death cases by 
focusing on 184 genes associated with heart disease by 
the WES. They found that there were different variants 
of the DCHS1 gene in one of these individuals, which are 
involved in mitral valve prolapse [26]. Besides, in agree-
ment with our result, Freed et  al. have examined five 
generations of a large family and found that at least 12 
members had mitral valve prolapse without any manifes-
tation of connective tissue abnormalities [27].
Conclusion
Secondary findings are very important and must be con-
sidered differently from sequencing results in a diagnostic 
setting. Secondary findings can be especially important 
in the autosomal-dominant state because autosomal-
dominant pattern can be affected by unique features such 
as incomplete penetrance or variable expression, which 
may explain the absence of clinical manifestations dur-
ing the experiment and this is controversial. Finally, in 
addition to the benefits of identifying secondary find-
ings, there are some important points to consider: (1) 
they need approval in families, (2) some of them may be 
related to the primary disease, and (3) they may carry a 
psychological burden.
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